Low-Dose Naltrexone Cost in Nevada (2026): Prices, Insurance, and Access

What Low-Dose Naltrexone Actually Costs in Nevada

The average cash price for compounded low-dose naltrexone in Nevada sits near $50 per month in 2026, based on 503A compounding pharmacy pricing for standard 1.5 mg to 4.5 mg oral capsules. This figure is consistent across most licensed compounding pharmacies operating in the state.

Naltrexone itself is an FDA-approved medication at its standard 50 mg dose for opioid use disorder and alcohol dependence 1. The "low-dose" formulation (typically 1.5 mg to 4.5 mg) is not commercially manufactured at those strengths, which is why patients must obtain it through compounding pharmacies. A pilot study by Younger et al. first demonstrated that LDN at 4.5 mg/day reduced fibromyalgia symptoms by 32.5% compared to placebo over 12 weeks (N=31) 2. That early trial opened the door for off-label investigation across multiple inflammatory and autoimmune conditions.

Price variation exists. Some online 503A pharmacies offer 90-day supplies for $90 to $120, bringing the effective monthly cost to $30 to $40. Walk-in compounding pharmacies in Las Vegas and Reno may charge $45 to $60 per month depending on the specific dose, capsule count, and any added ingredients like slow-release agents. Standard naltrexone 50 mg tablets, by contrast, are available generically for as little as $25 to $40 per month at chain pharmacies 3, but those tablets require splitting or dilution, which introduces dosing inconsistencies that compounding avoids.

Why LDN Requires Compounding and What That Means for Price

LDN must be compounded because no manufacturer produces naltrexone in capsules below 50 mg. The FDA regulates compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits licensed pharmacies to prepare patient-specific prescriptions 4. Nevada's State Board of Pharmacy oversees 503A-licensed compounding pharmacies operating within state borders.

Compounding means the price is not set by a drug manufacturer. Each pharmacy determines its own pricing based on raw naltrexone powder cost, labor, capsule type, and overhead. This is why LDN prices can range from $30 to $60 per month across different Nevada pharmacies. Raw naltrexone hydrochloride powder is inexpensive, often costing pharmacies less than $1 per gram. A 4.5 mg capsule uses a tiny fraction of that gram, so the bulk of the retail price reflects compounding labor, quality testing, and dispensing fees.

Some patients attempt to reduce costs by purchasing 50 mg generic tablets and using a "DIY dilution" method. The Endocrine Society and other professional bodies have not endorsed this approach, and the FDA has cautioned that drug manipulation outside pharmacy settings raises potency and safety concerns 5. For a medication dosed at the microgram-sensitive range of 1.5 mg to 4.5 mg, even small deviations can shift the pharmacologic effect from immune-modulating to opioid-receptor-blocking.

Nevada Medicaid and LDN: Current Coverage Status

Nevada Medicaid does not cover low-dose naltrexone for off-label indications such as fibromyalgia, autoimmune disease, or chronic inflammation. This is consistent with most state Medicaid programs nationwide.

The coverage gap exists for two reasons. First, LDN is prescribed off-label, and Medicaid formularies generally require FDA approval for the specific indication before granting coverage. Naltrexone carries FDA approval only for opioid use disorder (50 mg oral) and alcohol dependence 1. Second, compounded medications face additional Medicaid barriers because they lack National Drug Codes (NDCs) in the standard format that Medicaid billing systems require. The Centers for Medicare & Medicaid Services (CMS) has acknowledged these billing challenges in its guidance on compounded drug coverage 6.

Patients enrolled in Nevada Medicaid who want LDN must pay out of pocket. At $50 per month, the annual cost is approximately $600. Some compounding pharmacies offer subscription pricing or multi-month discounts that can reduce annual spending to $360 to $480. A randomized controlled trial by Younger et al. (2013) in 28 women with fibromyalgia showed LDN 4.5 mg produced a 28.8% reduction in pain scores versus placebo 7, data that patients may find useful when discussing the cost-benefit calculation with their providers.

Private Insurance Coverage for LDN in Nevada

Most private insurers in Nevada do not cover compounded LDN on their standard formularies. Off-label use and compounded status create a double barrier to coverage.

Some patients have obtained partial coverage through prior authorization (PA) appeals. A PA request typically requires the prescribing physician to document that the patient has failed first-line therapies, attach supporting literature, and specify the clinical rationale. The American Academy of Family Physicians (AAFP) notes that prior authorization processes for off-label medications vary significantly by insurer and often require persistence 8.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) can be used to pay for LDN because it is a prescribed medication. For Nevada residents on high-deductible health plans, channeling LDN expenses through an HSA provides a tax advantage of 22% to 37% depending on their marginal federal income tax bracket. That effectively drops a $50 monthly cost to $31.50 to $39 per month in after-tax dollars.

A 2022 systematic review published in the Journal of Clinical Medicine identified 89 published studies on LDN across pain, inflammatory, and neurological conditions, confirming growing clinical interest even as insurance coverage lags behind prescribing trends 9.

Telehealth Access to LDN in Nevada

Nevada permits telehealth prescribing of low-dose naltrexone statewide. A licensed prescriber can evaluate a patient via synchronous audio-video visit and write an LDN prescription that the patient fills at any licensed 503A compounding pharmacy, including out-of-state pharmacies that ship to Nevada.

Nevada's telehealth parity law (NRS 629.515) requires insurers to cover telehealth visits at the same rate as in-person visits 10. While this does not guarantee LDN drug coverage, it does mean the consultation itself should be covered by insurance. This is an important distinction: the visit may cost $0 with insurance, while the medication remains a cash-pay expense.

Telehealth platforms specializing in LDN prescribing typically charge $99 to $199 for an initial consultation and $49 to $99 for follow-ups. Some bundle the prescription with a partnered compounding pharmacy, offering combined consultation-plus-medication packages ranging from $75 to $125 per month. The Ryan Haight Online Pharmacy Consumer Protection Act requires a valid prescriber-patient relationship before controlled-substance prescribing via telehealth, but naltrexone is not a controlled substance 11, which simplifies the telehealth prescribing pathway.

How 503A Compounding Pharmacies Work in Nevada

A 503A pharmacy operates under a patient-specific prescription model. The pharmacist receives an individual prescription from a licensed prescriber, compounds the medication for that specific patient, and dispenses it directly. This distinguishes 503A pharmacies from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions 12.

Nevada's Board of Pharmacy licenses and inspects compounding pharmacies operating in the state. Patients can verify a pharmacy's license status through the Board's online lookup tool. For LDN specifically, patients should confirm that the pharmacy performs potency testing on compounded capsules, as dosing accuracy matters when working in the 1.5 mg to 4.5 mg range.

Most 503A pharmacies in Nevada ship statewide at no additional cost. Several national compounding pharmacies also ship to Nevada addresses, provided they hold the appropriate out-of-state pharmacy license from the Nevada Board of Pharmacy. This expands patient choice beyond local brick-and-mortar options in Las Vegas, Reno, Henderson, and Sparks.

A 2014 review in the British Journal of Pharmacology described LDN's proposed mechanism of action: transient opioid receptor blockade that upregulates endogenous opioid production and modulates Toll-like receptor 4 signaling on microglia, reducing neuroinflammation 13. Understanding this mechanism helps explain why precise compounding matters. Too high a dose blocks opioid receptors continuously rather than transiently, eliminating the rebound upregulation that produces LDN's therapeutic effect.

Clinical Evidence Supporting LDN

The evidence base for LDN spans multiple conditions, though most trials remain small. The original Younger et al. 2009 pilot (N=10) in fibromyalgia demonstrated a 30% improvement in symptoms versus baseline 2. A follow-up randomized, double-blind, placebo-controlled crossover trial by the same group (2013, N=28) confirmed a significant reduction in fibromyalgia pain (28.8% vs. placebo) 7.

In Crohn's disease, a pilot RCT by Smith et al. (2007, N=17) found that 89% of patients on LDN 4.5 mg showed clinical response at 12 weeks, compared to 40% on placebo 14. A subsequent trial by Smith et al. (2011, N=34) reported endoscopic improvement in 78% of LDN-treated patients versus 28% of placebo 15.

For multiple sclerosis, a phase II crossover trial by Cree et al. (2010, N=80) found that LDN 4.5 mg improved patient-reported quality of life, though it did not significantly change objective neurological measures 16. The National Institute of Neurological Disorders and Stroke (NINDS) at NIH has listed LDN among agents of interest for neuroimmune research 17.

Dr. Jarred Younger, the Stanford researcher who conducted the foundational fibromyalgia trials, has stated: "Low-dose naltrexone appears to work through a fundamentally different mechanism than standard pain medications, targeting glial cell activity rather than neuronal pain transmission" 2.

The Cochrane Library does not yet include a completed systematic review of LDN for any single indication, reflecting the field's early stage 18. The absence of large phase III trials is the primary reason insurance coverage has not materialized. Without FDA-approved labeling for specific conditions, payers have no regulatory mandate to cover LDN.

Cost Comparison: LDN vs. Common Alternatives

For fibromyalgia, FDA-approved medications include pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran (Savella). Generic pregabalin costs $15 to $40 per month; generic duloxetine runs $10 to $30 per month. Both carry FDA approval, insurance coverage, and larger evidence bases. LDN at $50 per month is more expensive on a cash-pay basis but may appeal to patients who have not responded to or cannot tolerate these first-line agents.

The AACE (American Association of Clinical Endocrinology) clinical practice guidelines emphasize individualized treatment selection based on patient response, tolerability, and comorbidities 19. For a Nevada patient paying cash for LDN, the total annual medication cost of approximately $600 compares to $120 to $480 for generic pregabalin or duloxetine. The price gap narrows when factoring in that LDN side effects are generally mild. The Younger 2013 trial reported that the most common adverse effects were vivid dreams and mild headache, with no serious adverse events 7.

Strategies to Reduce LDN Cost in Nevada

Several approaches can lower LDN expenses for Nevada residents. Comparing prices across multiple 503A compounding pharmacies is the simplest first step, as pricing varies by $15 to $25 per month for identical formulations.

Ordering 90-day supplies reduces per-month cost at most pharmacies. Some compounding pharmacies offer loyalty or subscription programs with 10% to 20% discounts for automatic refills. Paying through an HSA or FSA provides an immediate tax benefit. Telehealth platforms that bundle consultation and medication may offer lower combined costs than separate prescriber visits plus pharmacy purchases.

Patient assistance programs specifically for compounded LDN are rare, but some compounding pharmacies offer hardship pricing on a case-by-case basis. The LDN Research Trust, a UK-based nonprofit, maintains a directory of prescribers and pharmacies that may help patients identify cost-effective options 20.

The American Society of Health-System Pharmacists (ASHP) guidelines on compounding recommend that patients verify their pharmacy's accreditation, particularly Pharmacy Compounding Accreditation Board (PCAB) certification, to ensure quality and accurate dosing 21.

Nevada patients should ask their prescriber to write the prescription for a 90-day supply of naltrexone 4.5 mg capsules (or their specific dose), dispensed by a 503A compounding pharmacy, with refills authorized for 12 months. This single prescription structure minimizes follow-up visit costs and allows the patient to shop across pharmacies for the best price.